Ultragenyx Pharmaceutical Inc.
$22.79
The Read: Ultragenyx shares surged about 24% on positive regulatory progress and FDA acceptance of a resubmitted BLA for UX111, but then fell about 10% after Q1 2026 earnings missed revenue estimates due to seasonal Crysvita sales declines despite growth in Evkeeza and Dojolvi.
Price
Overlays
Panel
RARE
Hover to view data
No Data